MDACC Study No:2013-1041 ( NCT No: NCT02117219)
Title:A Phase 1 Study to Evaluate the Safety and Tolerability of MEDI4736 in Subjects with Myelodysplastic Syndrome after Treatment with Hypomethylating Agents
Principal Investigator:Guillermo Garcia-Manero
Treatment Agent:MEDI4736
Study Status:Open
Study Description:The goal of this clinical research study is to find the dose of MEDI4736 that
researchers think will work best in patients with MDS. The safety of this drug
will also be studied.

Researchers also want to learn about the safety, tolerability, and effects of
azacitidine in combination with MEDI4736 when given to patients whose disease
has gotten worse after receiving MEDI4736 alone.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I
Treatment Agents:MEDI4736
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:MedImmune LLC, a fully owned subsidiary of AstraZeneca
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Guillermo Garcia-Manero
For Clinical Trial Enrollment:713-745-3428
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults